Suppliers and packagers for generic pharmaceutical drug: RIFAPENTINE

RIFAPENTINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sanofi Aventis Us	PRIFTIN	rifapentine	TABLET;ORAL	021024	NDA	sanofi-aventis U.S. LLC	0088-2102-24	3 BLISTER PACK in 1 CARTON (0088-2102-24) / 8 TABLET, FILM COATED in 1 BLISTER PACK (0088-2102-01)	2017-02-08

Suppliers for the Pharmaceutical Drug: RIFAPENTINE

Last updated: August 15, 2025

Introduction

Rifapentine, a rifamycin derivative primarily prescribed for tuberculosis (TB) treatment, is a critical component in anti-tuberculosis therapy regimens. Its effectiveness stems from its ability to inhibit bacterial RNA synthesis, making it vital in multi-drug treatment plans that aim to curtail drug resistance. As global demand for rifapentine increases, particularly with the expansion of TB elimination programs, understanding the landscape of its suppliers becomes essential for healthcare providers, pharmaceutical companies, and policymakers. This report provides a comprehensive overview of the key suppliers of rifapentine, their manufacturing capabilities, geographic distribution, and market dynamics.

Manufacturing Overview and Market Landscape

The procurement of rifapentine predominantly involves a handful of major pharmaceutical manufacturers, with a handful of generic producers entering the market as patent protections expire or through licensing agreements. The landscape is characterized by active participation from both innovator companies and generic manufacturers, particularly from regions with strong pharmaceutical manufacturing bases such as India, China, and Europe.

Innovative Drug Manufacturers

The original patent for rifapentine was held by Johnson & Johnson, specifically through its subsidiary Janssen Pharmaceuticals. Janssen developed and marketed the brand-name product Priftin (marketed in some regions), which has been a significant supplier in high-income markets. Their manufacturing facilities in the United States and Europe adhere to stringent regulatory standards, including Good Manufacturing Practices (GMP) supervised by agencies such as the FDA and EMA.

Generic Manufacturers

Following patent expiration or licensing agreements, several generic pharmaceutical companies have entered the rifapentine supply chain:

• Lupin Limited (India): A prominent player in generic anti-tuberculosis drugs, Lupin manufactures rifapentine in line with WHO prequalification standards, expanding access in low- and middle-income countries (LMICs).

• Sandoz (Novartis): Sandoz produces generic rifapentine, often supplying formulations tailored for TB treatment programs. Their manufacturing plants in Europe and India meet international regulatory standards.

• Zhejiang Hisun Pharmaceutical Co., Ltd. (China): As part of China's growing pharmaceutical exports, Hisun has developed rifapentine formulations, aligning with WHO standards for quality and efficacy.

• Macleods Pharmaceuticals (India): Known for its robust portfolio of anti-TB medications, Macleods is another key supplier with capacity for large-scale production of rifapentine.

• Hetero Drugs (India): A major generic manufacturer with approvals for rifapentine, contributing to the availability of affordable TB medications in emerging markets.

WHO Prequalified and Regulatory Approvals

The World Health Organization (WHO) prequalification process significantly influences supplier credibility and market access, especially for procurement agencies and national TB programs. Several generic manufacturers have obtained WHO prequalification for rifapentine, notably Lupin and Macleods, facilitating their inclusion in global procurement schemes.

Geographic Distribution of Suppliers

Most rifapentine suppliers are concentrated in Asia, especially India and China, due to their cost-effective manufacturing infrastructure and focus on generic formulations. This regional concentration helps reduce costs and improve access in resource-limited settings. European and North American companies primarily focus on the innovator drug, with production quality controls aligned with Western regulatory standards.

Supply Chain Challenges and Opportunities

While manufacturing capacity has expanded, challenges such as raw material shortages, regulatory hurdles, and patent disputes periodically affect supply stability. Recently, the increased global focus on TB elimination has prompted efforts to diversify the supplier base and reinforce supply chains through strategic procurement and licensing agreements.

Key Suppliers in Different Markets

Supplier	Region	Role	Certification	Notes
Janssen Pharmaceuticals	Global	Innovator	FDA, EMA	Patent holder, high-cost but reliable supply in high-income markets
Lupin Limited	India	Generic	WHO PQ, CDSCO	Leading producer for LMICs, affordable pricing
Sandoz (Novartis)	Europe/India	Generic	WHO PQ, EMA	Focus on global health programs
Zhejiang Hisun Pharmaceutical	China	Generic	Local and international standards	Growing exports to emerging markets
Macleods Pharmaceuticals	India	Generic	WHO PQ	Large-scale manufacturing for TB programs
Hetero Drugs	India	Generic	Regulatory approvals	Expanding global footprint

Market Trends and Future Outlook

The global TB eradication initiatives have spurred increased demand for rifapentine, especially with the introduction of shorter-course regimens such as once-weekly rifapentine plus isoniazid for latent TB infection. This enhances the strategic importance of reliable suppliers able to meet quality, capacity, and affordability criteria.

Innovator companies like Janssen are actively engaged in licensing agreements to expand access. Simultaneously, generic manufacturers continue improving production technology, which may lead to price reductions and broader availability in endemic regions.

The market is also witnessing technological advances in synthetic processes, which could improve yield and reduce costs, further boosting supply stability. Moreover, international health agencies' procurement policies favor suppliers with WHO prequalification, incentivizing more manufacturers to seek certification.

Regulatory and Quality Considerations

Ensuring consistent quality across suppliers is critical due to rifapentine's role in life-saving TB regimens. Manufacturers must comply with stringent GMP standards and obtain global regulatory approvals. The WHO prequalification program serves as a benchmark, guiding procurement agencies toward verified suppliers and reducing risks associated with substandard medications.

Conclusion

The rifapentine supply ecosystem involves a core of established innovator manufacturers and a dynamic group of generic producers primarily based in India and China. While supply stability has improved over recent years, ongoing challenges such as raw material availability, regulatory harmonization, and patent landscapes require vigilant management. Expanding the supplier base, fostering licensing agreements, and maintaining quality standards remain pivotal in ensuring a consistent, affordable rifapentine supply for global TB control.

---

Key Takeaways

• Dominance of Indian and Chinese generic manufacturers like Lupin, Macleods, and Zhejiang Hisun substantially contribute to global rifapentine supplies, especially for LMICs.
• WHO prequalification remains a critical criterion for procurement, with several generic manufacturers achieving certification to ensure quality and market access.
• Patent expirations and licensing facilitate increased competition and lower prices, improving access in resource-limited settings.
• Supply chain resilience hinges on diversifying suppliers, streamlining regulatory pathways, and improving raw material availability.
• Future market growth aligns with global TB elimination goals, emphasizing innovation, licensing, and quality assurance in supplier development.

---

FAQs

1. Who are the leading suppliers of rifapentine globally?
Leading suppliers include Janssen Pharmaceuticals (innovator), Lupin Limited, Macleods Pharmaceuticals, Sandoz, and Zhejiang Hisun Pharmaceutical, primarily from India, China, and Europe.

2. How does WHO prequalification influence rifapentine supply?
WHO prequalification certifies manufacturing quality, facilitating procurement by international agencies and enabling suppliers to access global markets, especially in LMICs.

3. Are generic rifapentine drugs as effective as branded versions?
Yes. Approved generics meeting regulatory standards and WHO guidelines demonstrate bioequivalence and clinical efficacy comparable to branded counterparts.

4. What are the primary challenges in rifapentine supply chains?
Challenges include raw material shortages, regulatory delays, patent disputes, and manufacturing capacity limitations, which can impact supply stability.

5. What is the future outlook for rifapentine suppliers?
The market is poised for growth driven by international TB eradication efforts, technological innovations reducing costs, and licensing agreements expanding access in high-burden regions.

---

Sources

1. World Health Organization. (2022). WHO Prequalification of Tuberculosis Medicines. https://www.who.int/medicines/publications/WHO-PQ-TB/en/
2. Janssen Pharmaceuticals. (2023). Priftin Product Information.
3. Lupin Limited. (2023). Product Portfolio and Quality Certifications.
4. Sandoz. (2023). Generic Anti-tuberculosis Medications Overview.
5. Market reports on global TB drug market and supplier analysis, 2022-2023.

---

Note: This analysis is intended for informational purposes and reflects the current landscape based on publicly available data as of 2023.